(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

During the pandemic, money flooded into drugmakers’ shares but recently more investors are shifting into Big Tech ...

Today, anthrax remains one of the deadliest and easiest biological weapons to produce. Yet 80 percent of the U.S. supply of ...

Trump’s budget proposal, from May, seeks to slash the Department of Health and Human Services’ budget by $31.3 billion ...

Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Morgans healthcare and life sciences expert Iain Wilkie fills in for Scott Power this week, covering what the health movers ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...